cardio-oncology

Susan Dent, MD, receives the Thomas L. Force Pioneer Award from the International Cardio-Oncology Society (IC-OS).

The multi-institutional symposium will cover cardiovascular toxicities, risk stratification, and include case presentations. (for providers & researchers)

DCI cardio-oncologist Susan Dent, MD, is lead investigator for DCI-enrolled patients in this NIH-funded multi-site breast cancer study.

The burden of care after breast cancer treatment is on oncologists, other specialists & primary care providers. Here's a new Duke-edited guide for treating survivors.

The Duke Cardio-Oncology program hosts a webinar on identifying and managing cardio-toxicities in patients undergoing cancer treatment. CE is available.

DCI oncologists and researchers are supporting the Komen mission “for a cure” — fighting breast cancer on all fronts. Learn about their research.

For breast cancer patient Erin Hatcher, participating in a research study to learn about the potential for heart-related side effects of chemotherapy is a “win-win” situation to protect her health in the future.

Susan Dent, MD, co-director of the Duke Cardio-Oncology Program, is a leading international expert in the field. She is also associate director of Clinical Research in DCI's Breast Program.

The DCRI study is the first cardiovascular outcomes trial to compare two different types of cancer treatment.

What if beating breast cancer means weakening what beats in the chest?

Susan Dent, MD, FRCPC, is the new co-leader of Duke’s efforts in cardio-oncology and new associate director of breast cancer clinical research. She joined DCI in September 2018.

Cardiologist Chiara Melloni became interested in the emerging field of cardio-oncology after her father developed heart problems while being treated for lung cancer.